Veradigm Inc. · OTC:MDRX
Veradigm — J.P. Morgan Healthcare Conference 2023
30 slides from Veradigm's conference presentation, Jan 11, 2023
Slide 1: Veradigm J.P. Morgan Healthcare Conference
Veradigm J.P. Morgan Healthcare Conference January 11, 2023 Exh. 99.2
Slide 2: Forward-Looking Statements
Veradigm | Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our 2023 outlook. These forward-looking statements are based on the current beliefs and expectations
Slide 3: Who We Are
Copyright ©2023 Veradigm® | All rights reserved Who We Are
Slide 4: Our Mission
Our Mission At Veradigm we are transforming health, insightfully PAYER BIOPHARMA PROVIDER Veradigm is a healthcare technology and analytics company spanning across the three pillars of healthcare Differentiators are our connectivity, scale, and expertise
Slide 5: Enterprise Platform
Enterprise Platform Patient Engagement Practice Mgmt. & Rev Cycle Mgmt. Veradigm Provider Solutions Cloud EHR serves over 21,000 small practices Professional EHR serves over 2,100 complex practices 850 healthcare services organizations $100B processed charges Growth market among Cloud EHR practices
Slide 6: Our Provider Solutions Form Core of a Larger Veradigm Network
Our Provider Solutions Form Core of a Larger Veradigm Network Other Practice Solutions = 60K Proprietary Registries = 20K Healthcare IT Partners = 170K Collectively, serve 330K+ HEALTHCARE PROVIDERS & ~180M PATIENTS via the Veradigm Network EHR Providers = 80K
Slide 7: The Veradigm Formula
The Veradigm Formula Unique Ability to Drive Efficiencies; Build Awareness; Enhance Decision Making at the Point of Care Provider Scale Workflow Connectivity Analytics For Payers and Life Sciences Companies
Slide 8: Veradigm Payer
100+ health plan clients 9 of top 20 health plans 30M+ members across the US Veradigm Payer Our insightful solutions lead to better patient outcomes, increased revenue, and lower costs Our Payer focused solutions connect to more than 275K Providers across the US Solutions address Medicare Advantage,
Slide 9: End to End Payer Solutions
End to End Payer Solutions End to End Solution Value Layering $3 $2 $1 $ AVG. PER MEMBER PER MONTH Submissions Provider Engagement Risk & Quality Analytics Data Organization PAYMENT Submissions enable the Health Plan to get paid ACTIVATION The activation of the provider and the member to get the res
Slide 10: Veradigm Life Science
Provide data and registry information (ACC) as standalone or combined data sets We perform registry and study implementation services via our RWE Consulting group Digital Health Media serves agencies and direct sponsors by providing ads via our Provider platforms Veradigm Life Science Leverage Real-
Slide 11: Leader in Digital Media – Point of Care Messaging
Leader in Digital Media – Point of Care Messaging Biopharma companies working with Veradigm for point-of-care media Years delivering multi-platform point-of-care media Campaigns successfully executed over 11 years Ad impressions served since 2011 20B+ 100+ 11+ 1K+
Slide 12: How Do We Expect To Grow
Copyright ©2023 Veradigm® | All rights reserved How Do We Expect To Grow
Slide 13: Market Trends Accelerate Our Growth Strategy
Market Trends Accelerate Our Growth Strategy MOVE TO OUTPATIENT AND AMBULATORY CARE CHANGING INTEROPERABILITY STANDARDS INCREASE IN HEALTHCARE SPENDING DYNAMIC REGULATORY ENVIRONMENT GROWTH STRATEGY Leverage Convergence of Healthcare Market and the Transition to Value-Based Care EXPANDING USE OF REA
Slide 14: Veradigm's Competitive Advantages
Veradigm’s Competitive Advantages Patented Risk Adjustment Methodology with dynamic intervention planning empowers Payers to identify actionable interventions Easy-to-use, intuitive Clinical, Financial, Revenue Cycle and Patient Engagement solutions designed for Independent Providers Scalable access
Slide 15: Payer Data & Analytics | Large Addressable Market
Payer Data & Analytics| Large Addressable Market Veradigm Current $3.3B Addressable Payer Data and Analytics Market Segment Expected to Grow 20%+ Annually Total Opportunity Payer Spend on Software and IT Services in Healthcare ~$19B Current Veradigm Opportunity ~$3.3B Payer Solutions Growth Drivers
Slide 16: Rich Real-World Data at the Point-of-Care
Derived from Veradigm Network ambulatory EHRs One of the largest deidentified EHR datasets Extensive nationally distributed patient population from a wide range of practice sizes Supports patient longitudinal analysis, stand-alone or linked to other real-world data sources Rich Real-World Data at th
Slide 17: Financials
Copyright ©2023 Veradigm All rights reserved Financials
Slide 18: Veradigm Revenue Performance
Veradigm Revenue Performance FY 2021 YTD Q3’22 Revenue Growth 4.1% 6.2%
Slide 19: Margin Performance
Margin Performance 1 See reconciliation of non-GAAP metrics in the appendix of this presentation.
Slide 20: Free Cash Flow as a % of Revenue Accelerates
Free Cash Flow as a % of Revenue Accelerates 1 See reconciliation of non-GAAP metrics in the appendix of this presentation.
Slide 21: Significantly Reducing Share Count While Keeping Strong Cash
Significantly Reducing Share Count While Keeping Strong Cash 1 See reconciliation of non-GAAP metrics in the appendix of this presentation.
Slide 22: Veradigm 2023 Guidance and Share Repurchase Program
Veradigm 2023 Guidance and Share Repurchase Program Board Approved New Share Repurchase Program: Company may purchase up to $250 million of common stock 2023 Financial Guidance: Revenue expected between $640 million and $660 million Non-GAAP earnings per share expected between $0.90 and $1.00
Slide 23: Q&A
Copyright ©2023 Veradigm® | All rights reserved Q&A
Slide 24: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations
Slide 25: Non-GAAP Reconciliations (Adjusted EBITDA)
Non-GAAP Reconciliations (Adjusted EBITDA)
Slide 26: Non-GAAP Reconciliations (Free Cash Flow & Free Cash Flow as a % of Revenue)
Non-GAAP Reconciliations (Free Cash Flow & Free Cash Flow as a % of Revenue)
Slide 27: Non-GAAP Reconciliations (Non-GAAP diluted shares outstanding)
Non-GAAP Reconciliations (Non-GAAP diluted shares outstanding)
Slide 28: Non-GAAP Financial Measures
Veradigm | Non-GAAP Financial Measures Veradigm reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Veradigm presents gross profit, gross margin, income from operations, Adjusted EBITDA, Adjusted EBITDA margin, dilu
Slide 29: Non-GAAP Financial Measures
Veradigm | Non-GAAP Financial Measures Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Veradigm excludes acquisition-related amortization expen
Slide 30: Non-GAAP Financial Measures
Veradigm | Non-GAAP Financial Measures Management also believes that non-GAAP gross profit, gross margin, income from operations, Adjusted EBITDA, Adjusted EBITDA margin, diluted earnings per share, diluted weighted shares outstanding, and free cash flow and free cash flow as a percentage of revenue